article thumbnail

STAT+: Wegovy is among drugs set to be targeted in the next round of Medicare price negotiations, researchers say

STAT

The GLP-1 drug Wegovy tops the list of medications expected to be included in the next round of Medicare price negotiations, according to a paper in the Journal of Managed Care & Specialty Pharmacy.  1, and the negotiated prices of those drugs take effect in 2027.  Medicare will announce that list by Feb.

article thumbnail

NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027

Putting Patients First Blog

Clarification on QALY Metrics The NHC appreciates CMS’ commitment to excluding Quality-Adjusted Life Years (QALYs) from the negotiation process as outlined in the 2027 draft guidance. Valuing life differently based on disability status, age, or other special populations is inappropriate.

article thumbnail

Is Infusion Pharmacy Right For You?

The Happy PharmD

Did you know that the infusion pharmacy market is projected to reach $20 billion dollars by 2027? In this article, we delve into the world of infusion pharmacy, exploring salary prospects, job satisfaction, market demand, and career flexibility. Many pharmacists wonder how this growth could impact their careers.